Table of Contents

An erratum for this article has been published. To view the erratum, please click here.

ISRN Obstetrics and Gynecology
Volume 2011, Article ID 872434, 6 pages
Review Article

Robot-Assisted Radical Hysterectomy for Cervical Cancer: Review of Surgical and Oncological Outcomes

1Minimally Invasive Gynecological Surgery Unit, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
2Department of Obstetrics and Gynecology, Civil Hospital, 41049 Sassuolo, Italy
3Department of Urology, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy

Received 4 August 2011; Accepted 17 September 2011

Academic Editors: J. L. Neyro and D. Schust

Copyright © 2011 Seracchioli Renato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Robot-assisted procedures are being increasingly incorporated in gynaecologic oncology. Several studies have confirmed the feasibility and safety of robotic radical hysterectomy for selected patients with early-stage cervical cancer. It has been demonstrated that robotic radical hysterectomy offers an advantage over other surgical approaches with regard to operative time, blood loss, and hospital stay. Also initial evidences concerning oncological outcomes seem to confirm the equivalence to traditional open technique. Despite the fact that costs of robotic system are still high, they could be partially offset by several health-related and social benefits: less pain, faster dismissal, and return to full activity than other surgical approaches. The development of robotic technology may facilitate the spread of minimally invasive surgery in gynaecological oncology, overcoming some drawbacks of laparoscopic technique for challenging intervention such as radical hysterectomy. Further studies are needed to evaluate overall and disease-free survival of this technique and associated morbidity after adjuvant therapies.